EPHX2 and chronic kidney disease: In a CD1 mouse model where ischemic AKI progressing to CKD, treatment with the sEH inhibitor TPPU effectively controlled elevated blood pressure and glomerulosclerosis, but it enhanced renal perfusion injury, leading to increased inflammation and tubulointerstitial fibrosis (78).